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Abstract
Background: Nephrotic syndrome confers an acquired prothrombotic phenotype due to the urinary loss of
anticoagulant proteins.Patients with reactivation of nephrotic syndrome may develop thrombosis.
Case presentation: We report the case of a life-threatening cerebral venous thrombosis in a 13 year-old boy
affected by a relapse of nephrotic syndrome during a P. aeruginosa otitis/mastoiditis. Due to the worsening general
conditions and the severe neurological impairment, a course of systemic thrombolysis was successfully
administered, followed by anticoagulant therapy. In the present case severe inherited thrombophilia (inherited
dysfunctional protein S deficiency) was identified as an important additional risk factors for thrombosis.
Conclusions: A careful evalutaion of risk factos for thrombosi during reactivation of nephrotic syndrome include
measurement of plasma anticaogulant proteins. When low, antithrombotic prophylaxis with heparin should be
considered to prevent thrombotic episodes.
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Background
Venous thromboembolism is a rare condition in children,
with an incidence of 0.7 to 1.4 events per 100,000 individ-
uals [1] and up to 58 cases per 10,000 hospital admission
[2]. Recognized risk factors for thrombosis in children are
cancer, surgery, central venous catheters, thrombophilia
abnormalities, local compression of the veins and systemic
diseases [3, 4]. Among the latter nephrotic syndrome is
characterized by coagulation impairment, due to the loss
of the main circulating natural anticoagulant proteins of
relatively low molecular weight, i.e., antithrombin and
protein S [5]. Conflicting data are available on plasma
levels of protein C, another naturally occurring anticoagu-
lant protein, in patients with nephrotic syndrome. The
hypercoagulable state is enhanced by increased plasma
levels of fibrinogen and other procoagulant proteins, such
as von Willebrand factor, factor VIII and factor V, that are
retained by the kidney because of their high molecular
weight. The prothrombotic imbalance has also been
confirmed by the increase of thrombin generation and
fibrin deposition [6]. Furthermore, it has been reported
that in patients with nephrotic syndrome not only
secondary but also primary hemostasis is impaired.
Thrombocytosis is common, and an increased platelet
reactivity, the presence of circulating platelets exposing
the procoagulant phosphatidylserine and an increased
expression of activated glycoprotein IIb-IIIa on the
platelet surface have been reported [5].
A recent large case control study carried out in adults
with nephrotic syndrome showed an approximately 3-fold
increased risk of venous thromboembolism [7]. In chil-
dren, the occurrence of venous thromboembolic events
has been reported in several case series of patients with
active disease. Zhang et al. [8] found a 19 % of prevalence
of pulmonary embolism and/or renal vein thrombosis in
80 children with nephrotic syndrome that underwent
total-body CT scan. Kerlin et al [9] reported that 9.2 % of
326 children with nephrotic syndrome developed at least
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one episode of thrombosis, all but one in the venous
district. Cerebral vein thrombosis, a rare life-threatening
thrombotic manifestation, can complicate nephrotic
syndrome. In a case series of 34 children with thrombosis,
31.4 % of the events occurred in the cerebral veins [10].
Proteinuria, low plasma albumin levels (<2 g/dl), infec-
tions, anemia and the histological pattern of nephrotic
syndrome (membranous nephropathy being the worse)
are associated with an increased risk to develop throm-
bosis during the acute phase of the disease. The presence
of antiphospholipid antibodies is an additional risk factors
for thrombosis in children with nephrotic syndrome
associated with systemic lupus erythematosus.
Although the vast majority of thrombotic events in
children are in the venous district, expert opinions
and guidelines differ as regards the optimal antithrom-
botic strategy. Some guidelines advice to use anti-
thrombotic prophylaxis with aspirin in children with
mild active nephrotic syndrome and with warfarin in
severe cases (www.soc-nephrologie.org/PDF/epro/refe
rence/SNI/PNDS-SNI-enfant.pdf ). The efficacy of as-
pirin in primary prevention of venous thrombosis is not
demonstrated. Moreover, such antithrombotic prophylaxis
was used only in 21.5 % of patient included in a recent
large Italian cohort study [11].
Case Presentation
The patient was diagnosed with nephrotic syndrome at
the age of 3 years, after the occurrence of generalized
edema, proteinuria and transient kidney function impair-
ment during an episode of bilateral bacterial otitis. Three
years later a renal biopsy performed because of steroid-
dependency, showed a mild diffuse mesangial proliferation
with small areas of focal sclerosis in 14 % of the glomeruli.
During childhood he had a steroid-dependent course, with
relapses following common pediatric infections, and at the
age of 6 years cyclosporin A was added to corticosteroids.
No further episodes of nephrotic syndrome were re-
ported, till the age of 13 years when the patient was admit-
ted to the Pediatric Ward because of fever (up to 38.8 °C)
and productive cough accompanied by nephrotic range
proteinuria. Blood tests showed leucocytosis (15.7 WBC/
mm3), high CRP (3.7 mg/dl), fibrinogen (558 mg/dl) and
fibrin degradation products (9850 ng/ml). Large spectrum
antibiotic therapy was started and the ongoing doses of
prednisone and cyclosporine were increased. After few
days his neurologic conditions worsened and he developed
generalized seizures treated with phenobarbital. The pa-
tient was transferred to the Pediatric Intensive Care Unit
as ventilatory support was needed. A cerebral angio-MR
showed thrombosis of the superior sagittal, left transverse
and straight sinuses (Fig. 1a), with a concomitant inflam-
mation of the left mastoid process. Local thrombolysis
through a catether in the left jugular vein was attempted,
without success. Since the general conditions of the
patient were deteriorating rapidly, systemic thrombolysis
with recombinant tissue plasminogen activator (rtPA) was
administered intravenously at the dose of 0.3 mg/kg for
6 h. A subsequent cerebral angio-MR showed a complete
recanalization of the involved sinuses (Fig. 1b). In the
following days intravenous heparin was given in continu-
ous infusion (target range of activated partial thrombo-
plastin time ratio 1.5–2.5), that was switched to low
molecular weight heparin (calcium nadroparin 100 U/kg
bid) when the renal function normalized. P. aeruginosa
was isolated from the left ear swab and with a targeted
antibiotic therapy his general conditions improved steadily
until discharge. After few weeks phenobarbital was
discontinued and the patient switched from calcium
nadroparin to oral anticoagulant therapy with warfarin
Fig. 1 Angio-NMR before (a) and after (b) systemic thrombolysis. In panel A the superior sagittal, left trasverse and straight sinuses are not shown
because occluded by thrombi, whereas in panel B is shown a complete rehabitation of the involved sinuses after therapy
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(target range of International Normal Ratio [INR] of the
prothrombin time 2.0–3.0) for the following 6 months.
The change of anticoagulant therapy from heparin to
warfarin had not been done earlier because of the influ-
ence of phenobarbital on the INR.
Before starting warfarin the patients was tested for
thrombophilia including plasma levels of antithrombin,
protein C, protein S, the search of factor V Leiden and
prothrombin G20210A mutations, homocysteine lupus
anticoagulant and antiphospholipid antibodies (anticardio-
lipin and anti-β2 glycoprotein I antibodies IgG and IgM).
A type II (dysfunctional) protein S deficiency was diag-
nosed, with normal protein S antigen and low functional
levels. The inheritance of the deficiency was confirmed in
first- and second degree relatives (Fig. 2). Since the
episode of thrombosis the patient, who is now 17 year
old, had 5 further episodes of upper respiratory tract
infections, two of whom complicated by relapse of protein-
uria despite immunosuppressive maintenance treatment.
Antithrombotic prophylaxis with low-molecular-weight
heparin (100 UI/kg od) was given in both occasions.
Conclusions
We report the occurrence of a life-threatening cerebral
vein thrombosis in a 13 year-old boy during a reactivation
of nephrotic syndrome associated with bacterial otitis/
mastoiditis, successfully treated with systemic thromboly-
sis (rtPA) followed by anticoagulant therapy. Among risk
factors for thrombosis, other than inflammation and
nephrotic syndrome the patient was carrier of congenital
deficiency of protein S, one of the main circulating anti-
coagulant proteins, whose function in plasma was almost
half normal. We can surmise that the low baseline plasma
levels of the patients became even lower during the
reactivation of nephrotic syndrome because of the urinary
loss of the protein, further increasing the prothrombotic
phenotype, but unfortunately we did not measure protein
S at the time of thrombosis.
Antithrombotic prophylaxis with heparin is efficacious
in preventing thrombotic complications. Since venous
thrombosis in children is extremely rare, guidelines do not
support the use of heparin prophylaxis even in high risk
situations such as the first episodes or the relapse of neph-
rotic syndrome (www.soc-nephrologie.org/PDF/epro/refe
rence/SNI/PNDS-SNI-enfant.pdf) [11–13] as there is no
study addressing the best antithrombotic strategy. In
clinical practice aspirin is often administered, although its
efficacy in preventing venous thrombosis has not been
clearly demonstrated so far [11]. We believe it is crucial to
assess the individual profile of thrombotic risk, in
order to identify patients who can benefit most from
antithrombotic prophylaxis with heparin. Although
congenital deficiencies of the natural anticoagulant
proteins antithrombin, protein C and protein S are
present altogether only in approximately 1/1000 indi-
viduals in the general population [14], one should bear
in mind that these proteins can selectively decrease in
plasma during the relapse of nephrotic syndrome, and
therefore contribute to increase the risk of venous
thrombosis. Measurement of anticoagulant proteins
would help to evaluate the individual thrombotic risk
and tailor antithrombotic prophylaxis. Another important
patient characteristic to take into account is a family
history of thrombosis. Our patient had two family mem-
bers with venous thrombosis (the father and the paternal
grandmother) and this strongly suggests the likelihood
to detect a heritable thrombophilia abnormality. Having
tested protein S at admission and started antithrombotic
Fig. 2 Family tree of the patient. The arrow indicates the proband. Protein S functional (Fx; normal range 61–150 %) and antigen (Ag, normal
range 77–190 %) plasma levels are reported for each family member tested
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prophylaxis should potentially have avoided the onset of
thrombosis.
In conclusion, we believe that a careful assessment of
risk factors for thrombosis in children with acute neph-
rotic syndrome should include measurement of the anti-
coagulant proteins at admission and, if low, every 2–3
days until remission of the acute phase. Antithrombotic
prophylaxis with heparin should be considered in those
with low plasma levels of anticoagulant proteins, because
of its efficacy in preventing venous thrombosis and its
safety on the risk of bleeding [15].
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